Literature DB >> 10751036

Apparent lack of effect of P-glycoprotein on the gastrointestinal absorption of a substrate, tacrolimus, in normal mice.

W L Chiou1, S M Chung, T C Wu.   

Abstract

PURPOSE: To study the contribution of P-glycoprotein (P-gp) to the oral absorption of a substrate, tacrolimus, by comparing the extent and rate of bioavailability in normal and mdr1a knockout mice. Methods. Intravenous and oral (2 mg/kg) blood concentration data of tacrolimus in normal and knockout mice were obtained from a study by K. Yokogawa et al. in Pharm. Res. 16:1213-1218 (1999). Mean bioavailability (F), mean hepatic first-pass extraction ratio (Fh), mean bioavailability rates, mean oral clearance, and mean total hepatic intrinsic clearance were calculated using standard pharmacokinetic methods.
RESULTS: The mean F of tacrolimus (an apparently highly permeable compound) was increased from 0.22 in normal mice to 0.72 in knockout mice. These values were consistent with mean predicted Eh (based on intravenous data) of 0.77 and 0.27 in normal and knockout mice, respectively. Great similarity in the relative bioavailability profile (such as short Tmax) between normal and knockout mice was also found. Mean oral clearance and mean total or unbound hepatic intrinsic clearance of tacrolimus in knockout mice were found to be about 10 times lower compared to those in normal mice.
CONCLUSIONS: The above results suggest an apparent lack of effect of P-gp on the gastrointestinal absorption of tacrolimus in normal mice under the study condition. It is postulated that the effect of P-gp on the rate and extent of oral absorption should be more pronounced for those more slowly or incompletely absorbed drugs (i.e., drugs with relatively low permeabilities) as illustrated by talinolol in humans. The clearance data also suggest a very dominant role of P-glycoprotein in controlling the rate of hepatic metabolism of tacrolimus in normal mice, and P-glycoprotein may serve as an effective efflux pump for direct transport of metabolites formed in hepatocytes into the blood circulation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10751036     DOI: 10.1023/a:1007573531947

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  16 in total

1.  Commentary: a physiological approach to hepatic drug clearance.

Authors:  G R Wilkinson; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1975-10       Impact factor: 6.875

2.  Linear correlation of the fraction of oral dose absorbed of 64 drugs between humans and rats.

Authors:  W L Chiou; A Barve
Journal:  Pharm Res       Date:  1998-11       Impact factor: 4.200

3.  Disposition kinetics of griseofulvin in dogs.

Authors:  W L Chiou; S Riegelman
Journal:  J Pharm Sci       Date:  1969-12       Impact factor: 3.534

Review 4.  Physiological parameters in laboratory animals and humans.

Authors:  B Davies; T Morris
Journal:  Pharm Res       Date:  1993-07       Impact factor: 4.200

5.  New compartment- and model-independent method for rapid calculation of drug absorption rates.

Authors:  W L Chiou
Journal:  J Pharm Sci       Date:  1980-01       Impact factor: 3.534

6.  Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level--time curve.

Authors:  W L Chiou
Journal:  J Pharmacokinet Biopharm       Date:  1978-12

7.  Pharmacokinetics of FK-506, a novel immunosuppressant, after intravenous and oral administrations to rats.

Authors:  K Takada; H Usuda; M Oh-Hashi; H Yoshikawa; S Muranishi; H Tanaka
Journal:  J Pharmacobiodyn       Date:  1991-01

8.  Evaluation of using dog as an animal model to study the fraction of oral dose absorbed of 43 drugs in humans.

Authors:  W L Chiou; H Y Jeong; S M Chung; T C Wu
Journal:  Pharm Res       Date:  2000-02       Impact factor: 4.200

9.  P-glycoprotein-dependent disposition kinetics of tacrolimus: studies in mdr1a knockout mice.

Authors:  K Yokogawa; M Takahashi; I Tamai; H Konishi; M Nomura; S Moritani; K Miyamoto; A Tsuji
Journal:  Pharm Res       Date:  1999-08       Impact factor: 4.200

10.  The phenomenon and cause of the dose-dependent oral absorption of chlorothiazide in rats: extrapolation to human data based on the body surface area concept.

Authors:  F H Hsu; T Prueksaritanont; M G Lee; W L Chiou
Journal:  J Pharmacokinet Biopharm       Date:  1987-08
View more
  7 in total

1.  The rate and extent of oral bioavailability versus the rate and extent of oral absorption: clarification and recommendation of terminology.

Authors:  W L Chiou
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-02       Impact factor: 2.745

2.  Profound effect of plasma protein binding on the polarized transport of furosemide and verapamil in the Caco-2 model.

Authors:  S M Chung; E J Park; S M Swanson; T C Wu; W L Chiou
Journal:  Pharm Res       Date:  2001-04       Impact factor: 4.200

Review 3.  Theoretical predictions of drug absorption in drug discovery and development.

Authors:  Patric Stenberg; Christel A S Bergström; Kristina Luthman; Per Artursson
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 4.  Coexistence of passive and carrier-mediated processes in drug transport.

Authors:  Kiyohiko Sugano; Manfred Kansy; Per Artursson; Alex Avdeef; Stefanie Bendels; Li Di; Gerhard F Ecker; Bernard Faller; Holger Fischer; Grégori Gerebtzoff; Hans Lennernaes; Frank Senner
Journal:  Nat Rev Drug Discov       Date:  2010-08       Impact factor: 84.694

5.  Differentiation of gut and hepatic first-pass effect of drugs: 1. Studies of verapamil in ported dogs.

Authors:  Y H Lee; B A Perry; H S Lee; J R Kunta; J P Sutyak; P J Sinko
Journal:  Pharm Res       Date:  2001-12       Impact factor: 4.200

6.  Effect of stabilizer on the maximum degree and extent of supersaturation and oral absorption of tacrolimus made by ultra-rapid freezing.

Authors:  Kirk A Overhoff; Jason T McConville; Wei Yang; Keith P Johnston; Jay I Peters; Robert O Williams
Journal:  Pharm Res       Date:  2007-10-30       Impact factor: 4.200

7.  The H2 receptor antagonist nizatidine is a P-glycoprotein substrate: characterization of its intestinal epithelial cell efflux transport.

Authors:  Arik Dahan; Hairat Sabit; Gordon L Amidon
Journal:  AAPS J       Date:  2009-03-25       Impact factor: 4.009

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.